-
Enokizumab: Exploring Its Mechanism, Clinical Applications, and Biosimilar Advancements(Post)
Quick Facts About EnokizumabWhat is Enokizumab?Enokizumab is a monoclonal antibody designed to target interleukin-9 (IL-9), a cytokine involved in inflammatory responses. It has been stu
DNA Ligation(Page) VEGF: Inflammation and Tumourigenesis(Post)What is VEGF? Vascular Endothelial Growth Factors (VEGFs) are a group of homodimeric polypeptides, and are master regulators of vascular development, maintenance and a
Multiple Sclerosis and Stem Cells(Post)By Sonika Singh PhD candidate, University of Nottingham A Devastating Disease Multiple Sclerosis (MS) is a chronic and inflammatory disease based on
Colorectal Cancer Review (CRC) - Assay Genie(Post)By Charlotte O’Donnell PhD Cancer Carcinogenesis is a multi-step process that develops through epigenetic changes and muta
Tigatuzumab: Advancing Cancer Research with Targeted Therapies(Post)Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Kreuzreaktivität ELISA: Praxisleitfaden für Forschende(Post)Kreuzreaktivität ELISA: Praxisleitfaden für Forschende Kreuzreaktivität im ELISA bedeutet, dass ein Antikörper an ein strukturell ähnliches Nicht-Ziel bindet und dadurch falsch-positive oder verfälsc
Bone Resorption Explained: Process, Markers, and Clinical Insights(Post)Bone Biology · BiomarkersBone Resorption: Process, Markers & Clinical SignificanceBone resorption is the process by which osteoclasts break down bone tissue and release its stored minerals into the bl
Secukinumab: A Comprehensive Guide to Its Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons
Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword(Post)Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword In the intricate world of cancer biology, some of our body's most potent defense mechanisms can paradoxically turn against us. Cell
The Brain's Sentinels: How Microglia Shape Neuroinflammation in Disease(Post)The Brain's Sentinels: How Microglia Shape Neuroinflammation in Disease In the intricate landscape of the human brain, a silent, ever-watchful guardian stands ready to defend against injury and invas
ICOS: Stimulating the Immune System for Superior Cancer Therapy(Post)Immunotherapy has transformed the landscape of cancer treatment by leveraging the body’s immune system to target and destroy cancer cells. A key player in this process is Inducible T-cell
Tocilizumab (Actemra®) in COVID-19 Treatment(Post)Tocilizumab (Actemra®) in COVID-19 Treatment What is Tocilizumab? Tocilizumab, also called atlizumab, is an immunosuppress
The Interferonopathies and the Self-DNA Problem(Page) Senescence, the SASP and Immunosurveillance(Page) Lactobacilli - Structure, Metabolism, and Testing(Post)Microbiology · ProbioticsLactobacilli: Structure, Metabolism, Identification and Probiotic UseLactobacilli are lactic acid bacteria found in fermented foods and across the human gastrointestinal, oral
Glenzocimab: A Novel Antiplatelet Therapy for Stroke Prevention(Post)Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr
CD52 Expression(Post)What is CD52? Cluster Of Differentiation 52 (CD52) is a highly expressed membrane glycoprotein which is present on the surface of immune cell
Barrett’s Oesophagus to Oesophageal Adenocarcinoma – Review(Post)Oesophageal Adenocarcinoma is on the rise globally affecting more than 450,000 people worldwide (Pennathur, Gibson et al. 2013). Once diagnosed overall 5-year survival ranges from 15 % to 2